Visible and Subvisible Particulates in Injectables: What USP 788, 790 and 1790 Now Require

Every parenteral product carries a simple, non negotiable promise to the patient: what goes into the vein is the medicine, and nothing else. In the summer of 2026 that promise was broken often enough to make particulate contamination the recall theme of the quarter. Glass particles, glass fibres, steel, fibreglass and cellulose cotton fibre turned up in injectable products across several manufacturers, in both human and veterinary medicines, and in solutions pulled from United States and Canadian hospitals.

The timing was pointed. On 1 August 2026, United States Pharmacopeia General Chapter 788 became official under a new title, Subvisible Particulate Matter in Injections, closing a long harmonization effort with the European and Japanese pharmacopoeias. If your specifications, your visual inspection programme or your method references are out of date, this is the moment inspectors and auditors will notice. This article explains what USP 788, 790 and 1790 now require, what the 2026 recalls reveal about root cause, and how to build inspection and specification controls that hold up under Health Canada and FDA scrutiny.

Executive summary

USP 790 requires every unit of an injectable product to be visually inspected and to be essentially free of visible particulates. USP 788 sets the compendial limits and test methods for subvisible particles you cannot see with the naked eye. USP 1790 is the how to guide that ties the two together through inspection design, inspector qualification and statistical sampling. The 2026 recall cluster shows the failures are rarely exotic: glass quality, container and closure qualification, and the probability that a human inspector actually catches a defect. A defensible programme treats visible and subvisible particulate control as one connected system, supported by foreign matter CAPA and retained samples that can reconstruct what happened.

What visible and subvisible particulates are, and why regulators care

Particulate matter in injections is unwanted, mobile, undissolved material that is not a gas bubble and not part of the formulation. Visible particulates are large enough to be seen during inspection; subvisible particulates are smaller and are counted by instrument. Regulators care because injected particles can cause local irritation, phlebitis, granulomas, and in the worst cases embolism or organ damage, so both size ranges are controlled.

Particulates are usually grouped by source. Intrinsic particulates come from the product and its container closure system, for example glass delamination flakes, rubber or plastic from a stopper, or silicone oil. Extrinsic particulates are foreign to the process, such as cellulose fibre, hair or metal. Inherent particulates are associated with the product itself, which matters most for proteins and other biologics that can form visible or subvisible aggregates. The source of a particle usually points straight to its root cause, which is why identifying the material is the first analytical step after any finding.

For patients, the risk is not theoretical. FDA recall notices in 2026 described glass and fibre contamination as capable of causing pain and swelling at the injection site, inflammation of the veins, blood clots, and, in the most serious scenario, organ damage or death. That risk profile is why a visible particulate finding almost always drives a Type I or Type II recall rather than a quiet correction.

USP 788, 790 and 1790: how the three chapters fit together

USP 790 and USP 788 are enforceable general chapters that set requirements for visible and subvisible particulates. USP 1790 is an informational chapter that explains how to meet them. A compliant sterile product programme cites and follows all three: 790 for the 100 percent visible inspection, 788 for the subvisible limits, and 1790 for inspection design, inspector qualification and the sampling of accepted lots.

USP numbers its general chapters to signal status. Chapters numbered below 1000, including 788 and 790, carry mandatory requirements when a product is subject to them. Chapters numbered above 1000, including 1790, are informational guidance. That does not make 1790 optional in practice: it is the recognized description of good visual inspection, and an inspector will expect your programme to reflect it. The table below summarizes the three chapters.

The most significant recent change is to 788. Effective 1 August 2026, the chapter was renamed from Particulate Matter in Injections to Subvisible Particulate Matter in Injections, and its scope and definitions were aligned with European Pharmacopoeia 2.9.19 and the Japanese Pharmacopoeia through the Pharmacopeial Discussion Group. The core numerical limits and the two test methods, light obscuration and microscopic counting, did not change, but the definition of particulate matter was clarified as contamination and the applicability to intramuscular and subcutaneous routes was made explicit.

The practical consequence is a documentation exposure, not a new test. Laboratories must confirm which version of 788 their specifications, methods and certificates of analysis reference, and update controlled documents where the title or wording has changed. A specification that still cites the old chapter title is a finding waiting to happen, and it is an easy one for an auditor to spot.

The 2026 recall cluster: what glass, fibre and cellulose reveal

The 2026 injectable recalls were driven by foreign particulate matter reaching the finished container: glass particles, glass fibres and cellulose cotton fibre. They matter because the root causes recur across manufacturers, glass quality and container closure integrity, inspection probability, and supplier qualification, which means the lessons transfer directly to any sterile fill and finish operation.

Three FDA notices frame the pattern. On 10 August 2026, Fresenius Kabi recalled a lot of Tyenne (tocilizumab-aazg) injection after an internal investigation found glass particles in the product. On 31 July 2026, American Regent Animal Health recalled four lots of Adequan after visible glass fibre was found during testing of retained samples, a reminder that a recall can start inside your own laboratory, not in the field. And B. Braun issued a voluntary North American recall, covering United States and Canadian hospitals, of Excel Lactated Ringer's Injection after particulate identified primarily as cellulose cotton fibre was found in the solution.

Read together, these recalls map onto three failure modes an auditor will probe. Glass quality and container closure integrity: delamination, cracking and fibre shed from vials, cartridges and ampoules. Visual inspection capability: whether the inspection process could realistically detect the particle that reached the patient. Supplier and component qualification: whether the container, closure and process materials were controlled tightly enough to keep cellulose and metal out. Container closure integrity sits right beside particulate contamination as the other dominant sterile product failure mode, which is why we treat the two together in our container closure integrity testing work.

Building a visual inspection programme that survives an inspection

A defensible visual inspection programme inspects 100 percent of units, uses inspectors or equipment qualified against a known defect set, and accepts that detection is probabilistic. USP 790 requires the inspection; USP 1790 describes how to qualify it. The goal is a documented, repeatable process with a measured probability of detection, not a claim of zero defects that no inspection can honestly support.

Visual inspection is a statistical process. The chance of catching a given particle depends on its size, shape, colour, density and reflectivity, and on the container. As a rough benchmark drawn from the literature behind 1790, probability of detection climbs above 70 percent only once particles reach roughly 150 micrometres, and reaching 90 percent detection typically needs particles around 200 micrometres or larger. Smaller particles are missed more often, which is why the programme, not the individual inspector, has to be engineered.

The building blocks of an inspection programme that holds up are consistent across Health Canada and FDA expectations:

• 100 percent inspection. Every final container is inspected by a qualified manual, semi automated or automated method, and units with visible particulates are rejected.
• Inspector qualification. Inspectors are trained and qualified against a defect test set that includes known particulate standards, then requalified on a defined schedule and after any eyesight change.
• Defined defect library and classification. A photographic defect catalogue and an accept, reject and grey zone classification keep decisions consistent between inspectors and shifts.
• Probability of detection and sampling. Inspection is qualified to a measured probability of detection, and accepted lots are sampled to an acceptable quality limit to confirm the process kept the residual defect rate in control.
• Controlled conditions. Light intensity, background, inspection rate, viewing time and fatigue breaks are specified and monitored, because each one shifts the detection probability.
• Environmental and contamination controls. Cleanroom classification, gowning and component handling reduce the extrinsic particulates that inspection then has to catch.

Subvisible testing and specifications under USP 788

USP 788 controls the particles inspection cannot see, using light obscuration or microscopic counting against limits set by container volume. After the 1 August 2026 update, the compliance task is mostly documentary: confirm your methods, specifications and certificates cite the current chapter and title, and verify the method in your own laboratory.

Two method points cause most trouble in an audit. First, method suitability and verification: a compendial method still has to be shown to work for your specific product and container, especially for viscous or coloured solutions and for protein products where inherent aggregates complicate counting. Second, specification traceability: the finished product specification, the analytical method and the certificate of analysis must all point to the same, current version of 788. When a batch fails or a foreign particle is found, the subvisible data feed directly into the batch failure investigation, so the numbers and the method have to be defensible.

Foreign matter CAPA and root cause

When a particle reaches the container, the corrective and preventive action has to reach its true source, not just the symptom. Foreign matter CAPA identifies the material, traces it to an intrinsic, extrinsic or inherent origin, and corrects the container, component, process or inspection weakness that let it through. Weak CAPA that stops at increase inspection is the finding inspectors cite most.

Effective root cause work starts with identification. Material characterization, for example by microscopy or spectroscopy, tells you whether you are dealing with glass, cellulose, metal or a protein aggregate, and that answer usually points at the source: glass delamination or cracking, a shedding filter or garment, a poorly qualified stopper, or an unstable formulation. From there the CAPA has to change something durable, a container specification, a supplier qualification programme, a filtration step or an inspection parameter, and prove the change worked. CAPAs that keep failing almost always skipped the identification step or fixed a symptom, a pattern we see repeatedly in inspection findings.

Compliance checklist

Use this checklist to pressure test your visible and subvisible particulate controls before an inspector does.

• Specifications, methods and certificates cite the current USP 788, retitled Subvisible Particulate Matter in Injections and official 1 August 2026.
• USP 790 100 percent visible inspection is documented for every parenteral product, with essentially free acceptance criteria.
• Inspectors are qualified against a defect test set with known particulate standards, and requalified on schedule.
• Inspection is qualified to a measured probability of detection, and accepted lots are sampled to a defined acceptable quality limit.
• A photographic defect library and accept, reject and grey zone rules are in use and current.
• Light, background, rate and viewing time for inspection are specified, monitored and within qualified ranges.
• USP 788 methods are verified for your product and container, including viscous, coloured and protein products.
• Container and closure suppliers are qualified for glass quality, with delamination and fibre shed risk assessed.
• Foreign matter investigations identify the material before assigning root cause, and CAPA changes something durable.
• Reference and retention samples meet EU GMP Annex 19, applicable 24 September 2026, and can be pulled to investigate a suspect lot.

Common mistakes

• Citing the old chapter title. Specifications and certificates that still read Particulate Matter in Injections rather than Subvisible Particulate Matter in Injections are an easy documentary finding after 1 August 2026.
• Treating 1790 as optional. Because it is informational, some firms ignore it, then cannot explain how their inspection was qualified. Inspectors expect your programme to reflect it.
• Promising zero defects. Visual inspection is probabilistic. A specification of zero visible particles is not achievable and signals that the programme is not understood.
• Inspecting without inspector qualification. Running 100 percent inspection with inspectors who were never qualified against a defect set gives numbers no one can defend.
• Stopping CAPA at increase inspection. Adding inspection without identifying the particle and fixing the source is the classic ineffective CAPA.
• Neglecting retained samples. If you cannot pull and examine retained samples, a particulate signal becomes a full market recall instead of a bounded investigation.

Frequently asked questions

What is the difference between visible and subvisible particulates?

Visible particulates are large enough to be detected by the human eye during inspection and are controlled by USP 790, which requires products to be essentially free of them. Subvisible particulates are smaller, are counted by instrument such as light obscuration, and are controlled by USP 788 against numerical limits set by container type and volume. Both are managed together in a sterile product programme.

Did USP 788 change in 2026?

Yes. Effective 1 August 2026, USP 788 was retitled Subvisible Particulate Matter in Injections and harmonized with European Pharmacopoeia 2.9.19 and the Japanese Pharmacopoeia. The core limits and the two test methods, light obscuration and microscopic counting, did not change, but the definitions and route applicability were clarified. Laboratories should confirm their documents cite the current chapter.

Is USP 790 mandatory?

Yes. USP 790 is a general chapter numbered below 1000, so it carries mandatory requirements for injectable products subject to it. It requires 100 percent inspection of units and that products be essentially free of visible particulates, as also referenced in USP 1, Injections and Implanted Drug Products.

Can visual inspection guarantee that no particles are present?

No. Visual inspection is a probabilistic process. The likelihood of detecting a particle depends on its size, shape, colour, density and the container, and small particles are missed more often than large ones. A credible programme qualifies inspection to a measured probability of detection and samples accepted lots, rather than claiming zero defects.

What usually causes glass particles in an injectable?

Glass particulate commonly comes from the container itself, through delamination, cracking or fibre shed, or from mechanical stress during processing. Identifying the material by microscopy or spectroscopy points to the source, which is why container and closure supplier qualification and container closure integrity testing are central to prevention.

How do these requirements apply to Canadian manufacturers and importers?

Health Canada expects sterile products to meet recognized compendial standards, and Canadian licence holders that manufacture, import or distribute parenteral products should build visible and subvisible particulate controls into their quality system and inspection readiness. Products destined for multiple markets should meet USP, European Pharmacopoeia and Japanese Pharmacopoeia expectations, which the 2026 USP 788 harmonization has brought closer together.

How MFLRC can help

MF License and Regulatory Consultants helps sterile product manufacturers, importers and licence holders turn particulate control from a recall risk into a defensible system. Our team designs and reviews visual inspection SOPs, qualifies inspectors against defect standards, and verifies USP 788 methods for your specific products through our pharmaceutical validation and quality control services. We run foreign matter CAPA and root cause investigations, assess container and closure suppliers, and prepare your sterile operations for Health Canada and FDA inspection through gap assessments and audits.

Whether you are responding to a particulate finding, updating specifications for the 1 August 2026 USP 788 change, or building an inspection programme from the ground up, we provide practical, inspection ready deliverables rather than generic checklists. Explore our work with pharmaceutical clients or book a consultation to scope the support you need.

Conclusion

The 2026 recall cluster and the 1 August 2026 USP 788 update deliver the same message from two directions. Particulate control in injectables is not a single test or a single chapter; it is a connected system that spans visible inspection under 790, subvisible limits under 788, inspection design under 1790, container and supplier qualification, foreign matter CAPA, and retained samples. Firms that treat it that way find the defect before the patient does and keep a finding from becoming a recall. Firms that treat it as paperwork learn the difference during an inspection or a market action.

The near term action is concrete. Confirm your documents cite the current USP 788, verify your methods, qualify your inspectors to a defined probability of detection, and make sure your retained samples can answer the question every recall asks: what exactly was in the container, and how did it get there.

Sources and references

• USP, Particulate Contamination and Pharmacopeial Discussion Group harmonization (usp.org).
• USP General Chapter 790, Visible Particulates in Injections (doi.usp.org).
• USP General Chapter 1790, Visual Inspection of Injections (doi.usp.org).
• FDA, Inspection of Injectable Products for Visible Particulates, guidance for industry (fda.gov).
• FDA, Fresenius Kabi nationwide recall of Tyenne (tocilizumab-aazg) injection due to glass particles, 10 August 2026 (fda.gov).
• FDA, American Regent Animal Health nationwide recall of Adequan due to visible glass fibre, 31 July 2026 (fda.gov).
• FDA, B. Braun Medical voluntary North American recall of Excel Lactated Ringer's Injection due to particulate matter (fda.gov).